The ERα/KDM6B regulatory axis modulates osteogenic differentiation in human mesenchymal stem cells

Abstract

Osteoporosis is a highly prevalent public health burden associated with an increased risk of bone fracture, particularly in aging women. Estrogen, an important medicinal component for the preventative and therapeutic treatment of postmenopausal osteoporosis, induces osteogenesis by activating the estrogen receptor signaling pathway and upregulating the expression of osteogenic genes, such as bone morphogenetic proteins (BMPs). The epigenetic regulation of estrogen-mediated osteogenesis, however, is still unclear. In this report, we found that estrogen significantly induced the expression of lysine-specific demethylase 6B (KDM6B) and that KDM6B depletion by shRNAs led to a significant reduction in the osteogenic potential of DMSCs. Mechanistically, upon estrogen stimulation, estrogen receptor-α (ERα) was recruited to the KDM6B promoter, directly enhancing KDM6B expression. Subsequently, KDM6B was recruited to the BMP2 and HOXC6 promoters, resulting in the removal of H3K27me3 marks and activating the transcription of BMP2 and HOXC6, the master genes of osteogenic differentiation. Furthermore, we found that estrogen enhanced DMSC osteogenesis during calvarial bone regeneration and that estrogen’s pro-osteogenic effect was dependent on KDM6B in vivo. Taken together, our results demonstrate the vital role of the ERα/KDM6B regulatory axis in the epigenetic regulation of the estrogen-dependent osteogenic response.

References

[1] Amin S, Achenbach SJ, Atkinson EJ, Khosla S, Melton LJ 3rd. Trends in fracture incidence: a population-based study over 20 years. J. Bone Min. Res., 2014, 29: 581-589

[2] Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet, 2002, 359: 1761-1767

[3] Tu KN et al. Osteoporosis: a review of treatment options. P T, 2018, 43: 92-104

[4] McClung M et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am. J. Med., 2013, 126: 13-20

[5] Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin. Proc., 2009, 84: 632-637 quiz 638

[6] Reid IR. Efficacy, effectiveness and side effects of medications used to prevent fractures. J. Intern. Med., 2015, 277: 690-706

[7] Hillard TC, Whitcroft S, Ellerington MC, Whitehead MI. The long-term risks and benefits of hormone replacement therapy. J. Clin. Pharm. Ther., 1991, 16: 231-245

[8] Gambacciani M, Vacca F. Postmenopausal osteoporosis and hormone replacement therapy. Minerva Med., 2004, 95: 507-520

[9] Tuppurainen M. HT and SERMs in the long-term management of osteoporosis. Minerva Ginecol., 2012, 64: 195-205

[10] Pittenger MF et al. Multilineage potential of adult human mesenchymal stem cells. Science, 1999, 284: 143-147

[11] Gafni Y et al. Stem cells as vehicles for orthopedic gene therapy. Gene Ther., 2004, 11: 417-426

[12] Huang GT, Gronthos S, Shi S. Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. J. Dent. Res., 2009, 88: 792-806

[13] Rodriguez-Lozano FJ et al. Mesenchymal dental stem cells in regenerative dentistry. Med. Oral. Patol. Oral. Cir. Bucal., 2012, 17: e1062-e1067

[14] Liu H, Gronthos S, Shi S. Dental pulp stem cells. Methods Enzymol., 2006, 419: 99-113

[15] Cordeiro MM et al. Dental pulp tissue engineering with stem cells from exfoliated deciduous teeth. J. Endod., 2008, 34: 962-969

[16] Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends Mol. Med., 2013, 19: 197-209

[17] Krum SA. Direct transcriptional targets of sex steroid hormones in bone. J. Cell Biochem., 2011, 112: 401-408

[18] Popat VB et al. Bone mineral density in estrogen-deficient young women. J. Clin. Endocrinol. Metab., 2009, 94: 2277-2283

[19] Ejiri S et al. Estrogen deficiency and its effect on the jaw bones. J. Bone Min. Metab., 2008, 26: 409-415

[20] Zhou S et al. Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells. Mol. Endocrinol., 2003, 17: 56-66

[21] Chen FP, Hu CH, Wang KC. Estrogen modulates osteogenic activity and estrogen receptor mRNA in mesenchymal stem cells of women. Climacteric, 2013, 16: 154-160

[22] Soltanyzadeh M, Ghollasi M, Halabian R, Shams M. A comparative study of hBM‐MSCs’ differentiation toward osteogenic lineage in the presence of progesterone and estrogen hormones separately and concurrently in vitro. Cell Biol. Int., 2020, 44: 1701-1713

[23] Soltanyzadeh M, Salimi A, Halabian R, Ghollasi M. The effect of female sex steroid hormones on osteogenic differentiation of endometrial stem cells. Mol. Biol. Rep., 2020, 47: 3663-3674

[24] Lee HR, Kim TH, Choi KC. Functions and physiological roles of two types of estrogen receptors, ERalpha and ERbeta, identified by estrogen receptor knockout mouse. Lab Anim. Res., 2012, 28: 71-76

[25] Ye L et al. Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs. Cell Stem Cell, 2012, 11: 50-61

[26] Wang, R., Wang, Y., Zhu, L., Liu, Y. & Li, W. Epigenetic regulation in mesenchymal stem cell aging and differentiation and osteoporosis. Stem Cells Int. 2020, 8836258 (2020).

[27] Alam H, Gu B, Lee MG. Histone methylation modifiers in cellular signaling pathways. Cell Mol. Life Sci., 2015, 72: 4577-4592

[28] Igolkina, A. A. et al. H3K4me3, H3K9ac, H3K27ac, H3K27me3 and H3K9me3 histone tags suggest distinct regulatory evolution of open and condensed chromatin landmarks. Cells 8, 1034 (2019).

[29] Deng P, Chen QM, Hong C, Wang CY. Histone methyltransferases and demethylases: regulators in balancing osteogenic and adipogenic differentiation of mesenchymal stem cells. Int. J. Oral. Sci., 2015, 7: 197-204

[30] Swigut T, Wysocka J. H3K27 demethylases, at long last. Cell, 2007, 131: 29-32

[31] Sen GL, Webster DE, Barragan DI, Chang HY, Khavari PA. Control of differentiation in a self-renewing mammalian tissue by the histone demethylase JMJD3. Genes Dev., 2008, 22: 1865-1870

[32] Burgold T et al. The histone H3 lysine 27-specific demethylase Jmjd3 is required for neural commitment. PLoS One, 2008, 3: e3034

[33] Akizu N, Estaras C, Guerrero L, Marti E, Martinez-Balbas MA. H3K27me3 regulates BMP activity in developing spinal cord. Development, 2010, 137: 2915-2925

[34] Estaras C et al. Genome-wide analysis reveals that Smad3 and JMJD3 HDM co-activate the neural developmental program. Development, 2012, 139: 2681-2691

[35] Jiang W, Wang J, Zhang Y. Histone H3K27me3 demethylases KDM6A and KDM6B modulate definitive endoderm differentiation from human ESCs by regulating WNT signaling pathway. Cell Res., 2013, 23: 122-130

[36] Kartikasari AE et al. The histone demethylase Jmjd3 sequentially associates with the transcription factors Tbx3 and Eomes to drive endoderm differentiation. EMBO J., 2013, 32: 1393-1408

[37] Xu J, Yu B, Hong C, Wang CY. KDM6B epigenetically regulates odontogenic differentiation of dental mesenchymal stem cells. Int. J. Oral. Sci., 2013, 5: 200-205

[38] Hoang M et al. Alcohol-induced suppression of KDM6B dysregulates the mineralization potential in dental pulp stem cells. Stem Cell Res, 2016, 17: 111-121

[39] Hong L et al. 17-Beta estradiol enhances osteogenic and adipogenic differentiation of human adipose-derived stromal cells. Tissue Eng., 2007, 13: 1197-1203

[40] Fan JZ et al. Estrogen improves the proliferation and differentiation of hBMSCs derived from postmenopausal osteoporosis through notch signaling pathway. Mol. Cell Biochem., 2014, 392: 85-93

[41] Son Y-B et al. Evaluation of odonto/osteogenic differentiation potential from different regions derived dental tissue stem cells and effect of 17β-estradiol on efficiency. BMC Oral. Health, 2021, 21: 1-14

[42] Matsubara T et al. BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation. J. Biol. Chem., 2008, 283: 29119-29125

[43] Rickard DJ, Sullivan TA, Shenker BJ, Leboy PS, Kazhdan I. Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2. Dev. Biol., 1994, 161: 218-228

[44] Hong C et al. Reducing posttreatment relapse in cleft lip palatal expansion using an injectable estrogen-nanodiamond hydrogel. Proc. Natl. Acad. Sci. U. S. A., 2017, 114: E7218-E7225

[45] Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am. J. Obstet. Gynecol., 2006, 194: S3-S11

[46] Szeliga A, Maciejewska-Jeske M, Meczekalski B. Bone health and evaluation of bone mineral density in patients with premature ovarian insufficiency. Prz. Menopauzalny, 2018, 17: 112-116

[47] Agger K et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature, 2007, 449: 731-734

[48] Yang D, Okamura H, Nakashima Y, Haneji T. Histone demethylase Jmjd3 regulates osteoblast differentiation via transcription factors Runx2 and osterix. J. Biol. Chem., 2013, 288: 33530-33541

[49] Hassan MQ et al. HOXA10 controls osteoblastogenesis by directly activating bone regulatory and phenotypic genes. Mol. Cell Biol., 2007, 27: 3337-3352

[50] Miller SA, Mohn SE, Weinmann AS. Jmjd3 and UTX play a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression. Mol. Cell, 2010, 40: 594-605

[51] Zhao W et al. Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination. Cell, 2013, 152: 1037-1050

[52] Zhou J et al. miR-20a regulates adipocyte differentiation by targeting lysine-specific demethylase 6b and transforming growth factor-beta signaling. Int. J. Obes., 2015, 39: 1282-1291

[53] Lu CC et al. Developmental pathways and endothelial to mesenchymal transition in canine myxomatous mitral valve disease. Vet. J., 2015, 206: 377-384

[54] Yang D, Okamura H, Teramachi J, Haneji T. Histone demethylase Jmjd3 regulates osteoblast apoptosis through targeting anti-apoptotic protein Bcl-2 and pro-apoptotic protein Bim. Biochim. et. Biophys. acta, 2016, 1863: 650-659

[55] Arnal JF et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. Physiol. Rev., 2017, 97: 1045-1087

[56] Garcia-Bassets I et al. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell, 2007, 128: 505-518

[57] Wade MA et al. The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer. Nucleic Acids Res., 2015, 43: 196-207

[58] Gaughan L et al. KDM4B is a master regulator of the estrogen receptor signalling cascade. Nucleic Acids Res., 2013, 41: 6892-6904

[59] Kawazu M et al. Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PLoS One, 2011, 6: e17830

[60] Shi L et al. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc. Natl. Acad. Sci. U. S. A., 2011, 108: 7541-7546

[61] Svotelis A et al. H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERalpha ligand dependency. EMBO J., 2011, 30: 3947-3961

[62] Tang Y et al. MicroRNA-99a is a novel regulator of KDM6B-mediated osteogenic differentiation of BMSCs. J. Cell Mol. Med., 2018, 22: 2162-2176

[63] Huszar JM, Payne CJ. MIR146A inhibits JMJD3 expression and osteogenic differentiation in human mesenchymal stem cells. FEBS Lett., 2014, 588: 1850-1856

[64] Park BK et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat. Med., 2007, 13: 62-69

[65] Lee M et al. Biomimetic apatite-coated alginate/chitosan microparticles as osteogenic protein carriers. Biomaterials, 2009, 30: 6094-6101

[66] Park H et al. Anionic carbohydrate-containing chitosan scaffolds for bone regeneration. Carbohydr. Polym., 2013, 97: 587-596

[67] DeConde AS et al. Bone morphogenetic protein‐2–impregnated biomimetic scaffolds successfully induce bone healing in a marginal mandibular defect. Laryngoscope, 2013, 123: 1149-1155

[68] Yu B et al. PGC-1alpha controls skeletal stem cell fate and bone-fat balance in osteoporosis and skeletal aging by inducing TAZ. Cell Stem Cell, 2018, 23: 615-623

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR)(R01DE024828)

U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR)